Literature DB >> 31787819

Current Controversies in Large-Vessel Inflammatory Vasculitis and Thoracic Aortic Aneurysm Disease.

Amer Harky1, Matthew Fok2, Callum Howard3, Mohamad Bashir3.   

Abstract

Large-vessel vasculitis encompasses the spectrum of vasculitides, which pathologically cause chronic granulomatous inflammatory changes, primarily in the aorta and its major branches. These patients are at risk of developing life-threatening aortic lesions that, without recognition and prompt treatment, can cause detrimental effects. Many provocative issues surrounding large-vessel vasculitis and its surgical treatment still remain, spanning from recognition to management. In this review, we discuss the main large-vessel vasculitides, Takayasu's arteritis and giant cell arteritis. We include the key points and current controversies surrounding diagnostic imaging, timing of interventions, and patient outcomes. © Thieme Medical Publishers.

Entities:  

Keywords:  large vessel; thoracic aortic disease; vasculitis

Year:  2019        PMID: 31787819      PMCID: PMC6882665          DOI: 10.1055/s-0039-1692448

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  69 in total

1.  The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis.

Authors:  Myles Webb; Anthony Chambers; Adil AL-Nahhas; Justin C Mason; Lucy Maudlin; Lucy Rahman; John Frank
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

Review 2.  Is there a role for biomarkers in thoracic aortic aneurysm disease?

Authors:  Damian Balmforth; Amer Harky; Benjamin Adams; John Yap; Alex Shipolini; Neil Roberts; Rakesh Uppal; Mohamad Bashir
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-10-28

3.  CT angiography of Takayasu arteritis: comparison with conventional angiography.

Authors:  J H Park; J W Chung; K W Lee; Y B Park; M C Han
Journal:  J Vasc Interv Radiol       Date:  1997 May-Jun       Impact factor: 3.464

Review 4.  The role of toll like receptors in giant cell arteritis.

Authors:  Lorraine O'Neill; Eamonn S Molloy
Journal:  Rheumatology (Oxford)       Date:  2016-02-18       Impact factor: 7.580

5.  Takayasu's arteritis: a hospital-region based study on occurrence, treatment and prognosis.

Authors:  A U Waern; P Andersson; A Hemmingsson
Journal:  Angiology       Date:  1983-05       Impact factor: 3.619

6.  Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis.

Authors:  Hiroyuki Yamashita; Kazuo Kubota; Yuko Takahashi; Ryogo Minaminoto; Miyako Morooka; Kimiteru Ito; Toshikazu Kano; Hiroshi Kaneko; Hiroshi Takashima; Akio Mimoiri
Journal:  Mod Rheumatol       Date:  2011-12-29       Impact factor: 3.023

7.  Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences.

Authors:  Daisuke Tezuka; Go Haraguchi; Takashi Ishihara; Hirokazu Ohigashi; Hiroshi Inagaki; Jun-ichi Suzuki; Kenzo Hirao; Mitsuaki Isobe
Journal:  JACC Cardiovasc Imaging       Date:  2012-04

8.  Delayed diagnosis of biopsy-negative giant cell arteritis presenting as fever of unknown origin.

Authors:  Valentin S Schäfer; Kenneth J Warrington; Eric E Williamson; Tanaz A Kermani
Journal:  J Gen Intern Med       Date:  2009-02-18       Impact factor: 5.128

9.  IgG4- related disease: an orphan disease with many faces.

Authors:  Herwig Pieringer; Ilse Parzer; Adelheid Wöhrer; Petra Reis; Bastian Oppl; Jochen Zwerina
Journal:  Orphanet J Rare Dis       Date:  2014-07-16       Impact factor: 4.123

Review 10.  Epidemiology of vasculitides: differences between Japan, Europe and North America.

Authors:  Shigeto Kobayashi; Shouichi Fujimoto
Journal:  Clin Exp Nephrol       Date:  2013-05-30       Impact factor: 2.801

View more
  1 in total

1.  Familial risks between giant cell arteritis and Takayasu arteritis and other autoimmune diseases in the population of Sweden.

Authors:  Hauke Thomsen; Xinjun Li; Kristina Sundquist; Jan Sundquist; Asta Försti; Kari Hemminki
Journal:  Sci Rep       Date:  2020-11-30       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.